Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meda wins approval for seasonal allergic rhinitis drug
Astepro nasal spray is said to be an improvement over the marketed Astelin nasal spray and is better tolerated by patients using the new spray. Full launch of
Astepro nasal spray is said to be an improvement over the marketed Astelin nasal spray and is better tolerated by patients using the new spray. Full launch of
The collaboration will combine ZyGEM’s advanced enzymatic nucleic acid extraction technology and Advalytix’s expertise in single-cell molecular tests for life science research and diagnostic applications, said ZyGEM. Advalytix
The Horizons-AMI trial was a prospective, single-blind, randomized, multi-center study conducted in 11 countries. Patients undergoing angioplasty were randomly assigned to receive either Angiomax (bivalirudin) with provisional use
The new delivery device, approved by the FDA in June 2008, is being shipped to pharmacies and is available for patients when they fill their prescriptions in the
This patent was issued to Boehringer Ingelheim International, the developer of the invention, and expires on November 29, 2020. Elestat, a topical antihistamine with mast cell stabilizing and
According to Sound Surgical Technologies, the Vaser lipo system uses advanced ultrasonic energy to selectively break apart unwanted fat, while preserving other important tissue structures. Dan Goldberger, CEO
George Cox, president of Bolder BioTechnology, said: “We are grateful to receive continued support from the National Institute of Neurological Disorders and Stroke (NINDS) for our long-acting beta
The first patent covers a method for determining matching patterns within gene expression data stored in a database comprising of biological data. This methodology helps in retrieving clinically
RTA 402 is currently being studied in a Phase I/II trial in patients with pancreatic cancer, and is also in Phase II development for chronic kidney disease. Warren
This initial safety study will involve single injections of Protectan CBLB502 in ascending dose groups of six healthy volunteers each. Participants in the study will be assessed for